Posterior Segment Age-related Macular Degeneration Figure 3: Flow Cytometry44 40 A
Intracellular 16
14 12 10
4 6 8
2 0
Control
Extracellular 12
10
4 6 8
2 0
Control
Intracellular B
14 12 10
4 6 8
2 0
Beva Ranu 40 30 20 10 0 100 Control
Extracellular 10
4 6 8
2 0
Control Beva Ranu 0 100 Untreated A: 1 h clinical concentrations; B: 1 h 10 % of clinical concentrations. FL1-H = height of fluorescence intensity.
absorption after intraocular bevacizumab injection is a distinct possibility. Intravitreally injected IgGs were eliminated into the blood stream faster in laser-photocoagulated eyes versus normal control eyes owing to neonatal fragment crystallisable (Fc)-receptor upregulation in laser-photocoagulated retina. This increases the potential for Fc-mediated systemic transmission of bevacizumab from the eye into the circulation (see Figure 2).21,40
It can be concluded 36
from preclinical studies of anti-VEGF treatments that overlapping yet distinct pharmacological properties of ranibizumab and bevacizumab indicate that efficacy and safety data obtained for one drug cannot be extrapolated to the other.41
Bevacizumab was found to internalise and accumulate in porcine retinal pigment epithelial 42 cells in vitro 43. Such accumulation did not occur
EUROPEAN OPHTHALMIC REVIEW 101 FL1-H Ranibizumab Bevacizumab 102 103 Beva Ranu Untreated 40 30 20 10 101 FL1-H Ranibizumab Bevacizumab 102 103 + 30 20 10 0 100 Untreated 40 Beva Ranu 30 20 10 0 100 Untreated 101 FL1-H Ranibizumab Bevacizumab 102 103 101 FL1-H Ranibizumab Bevacizumab 102 103
Intensity
Intensity
Intensity
Intensity
Counts
Counts
Counts
Counts
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68